ECOG-ACRIN Cancer Research Group and PrECOG, LLC, will present multiple abstracts at the 66th American Society of Hematology (ASH) Meeting & Exposition, focusing on improved treatments for lymphoma and acute leukemias. The conference will be held in San Diego, California, and virtually from December 7-10, 2024.
Blinatumomab's Impact on B-Cell ALL
Updated data from the phase 3 E1910 trial will be presented, reinforcing the benefit of adding blinatumomab to standard front-line consolidation chemotherapy for older, newly diagnosed patients with BCR::ABL1 negative B-lineage acute lymphoblastic leukemia (ALL). The initial results of the E1910 trial led to FDA approval of blinatumomab in June 2024, demonstrating improved remission rates and overall survival. Dr. Nikolai A. Podoltsev from Yale University will present a poster (Abstract 4211) on Monday, December 9, detailing these findings.
Furthermore, Dr. Michaela Liedtke from Stanford University will present an oral abstract (Abstract 779) assessing outcomes of allogeneic stem cell transplantation by treatment arm in newly diagnosed measurable residual disease (MRD) negative patients with B-lineage ALL randomized to conventional chemotherapy +/- blinatumomab in the ECOG-ACRIN E1910 trial.
Gilteritinib versus Midostaurin in FLT3-Mutated AML
The phase 2 PrE0905 study, led by Dr. Selina M. Luger from the University of Pennsylvania, compares gilteritinib to midostaurin in newly diagnosed FLT3-mutated acute myeloid leukemia (AML). Results indicate that gilteritinib leads to higher remission and transplant rates compared to midostaurin. However, the post-induction mutational MRD negative rate was not significantly increased. These findings will be presented as oral abstract 221 on Saturday, December 7.
Acalabrutinib in Mantle Cell Lymphoma
The ECOG-ACRIN EA4181 trial, presented by Dr. Nina D. Wagner-Johnston from Johns Hopkins University, explores the addition or substitution of acalabrutinib in intensive frontline chemoimmunotherapy for patients ≤ 70 years old with mantle cell lymphoma. This 3-arm randomized phase 2 intergroup trial's outcomes will be shared in oral abstract 236 on Saturday, December 7.
Additional Research
Other notable presentations include research on EBF1 activity controlling leukemia sensitivity to inotuzumab ozogamicin (Abstract 830, presented by Dr. Carolin S. Escherich from St. Jude Children’s Research Hospital) and the safety and efficacy of ipilimumab, nivolumab, and brentuximab vedotin combinations in pediatric patients with relapsed/refractory classic Hodgkin lymphoma (Abstract 4427, presented by Dr. Christopher J. Forlenza from Memorial Sloan Kettering Cancer Center).
